Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVEKEO vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Treatment of acute cyanide poisoning,Off-label: Prevention of cyanide toxicity from sodium nitroprusside infusion
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Sodium nitrite is metabolized primarily to methemoglobin and nitric oxide. Sodium thiosulfate is metabolized to thiocyanate by rhodanese.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
40-50% bound to serum albumin and α1-acid glycoprotein.
~16% bound to plasma proteins (primarily albumin).
0.6-0.8 L/kg. Clinical meaning: Moderate distribution suggests limited tissue penetration; primarily confined to extracellular fluid.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral: 85-95%. Rectal: 70-80%. Intramuscular: 90-100%.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
No adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
No adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate or severe hepatic impairment (Child-Pugh B or C) due to limited data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Not approved for pediatric patients; safety and efficacy not established.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
No specific dose adjustment recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
Risk of severe hypotension and methemoglobinemia. Monitor methemoglobin levels. Use caution in patients with low oxygen saturation.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Can cause severe hypotension requiring vasopressors,Methemoglobinemia may reduce oxygen delivery; avoid in patients with significant anemia or G6PD deficiency,Thiocyanate accumulation with prolonged use, especially in renal impairment
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to sodium nitrite or sodium thiosulfate,Methemoglobin reductase deficiency
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
No known food interactions. EVEKEO is administered intravenously and is not affected by oral intake. However, in neonates, careful monitoring of electrolyte and fluid balance is important.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second and third trimesters unknown.
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
No data on excretion in human milk. M/P ratio unknown. Caution if breastfeeding; consider risk vs benefit.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
No pharmacokinetic studies in pregnancy; dose adjustment recommendations not established. Use lowest effective dose and shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
EVEKEO is a beta-adrenergic agonist indicated for the treatment of bradycardia in premature neonates. It is given intravenously and has a rapid onset of action (1-2 minutes). Monitor heart rate and blood pressure continuously during infusion. Use with caution in patients with hyperthyroidism, diabetes, or history of seizures. Tachyphylaxis may develop with prolonged use.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
This medication is for hospital use only and will be given by a healthcare professional.,It is used to increase your baby's heart rate and improve blood flow.,The dose may be adjusted based on your baby's response and heart rate.,Potential side effects include increased heart rate, high blood pressure, or arrhythmias.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVEKEO vs ADDERALL 5, answered by our medical review team.
EVEKEO is a CNS Stimulant that works by EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVEKEO and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVEKEO is: 5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVEKEO and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVEKEO is classified as Category C. Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second . ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.